Moderna (MRNA) said late Friday it filed an application with the US Food and Drug Administration for review of its Spikevax formula targeting SARS-CoV-2 variant LP.8.1.
The application is based on FDA guidance updating COVID-19 vaccines to a monovalent JN.1 lineage, with a preference for the LP.8.1.
The most common adverse reactions were headache, fatigue, myalgia, chills, arthralgia, axillary swelling, nausea, and fever.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.